A. Brandes, A. Tosoni, E. Franceschi, M. Reni, G. Gatta et al., Glioblastoma in adults, Critical Reviews in Oncology/Hematology, vol.67, issue.2, pp.139-52, 2008.
DOI : 10.1016/j.critrevonc.2008.02.005

D. Figarella-branger and C. Bouvier, Histological classification of human gliomas: state of art and controversies], Bull Cancer, vol.92, issue.4, pp.301-310, 2005.

D. Psimaras and J. Delattre, Perspectives in diagnosis and management of malignant gliomas]. Cancer Radiothérapie J Société Fr Radiothérapie Oncol, pp.6-7695, 2008.

R. Stupp, A. Pica, R. Mirimanoff, and O. Michielin, [A practical guide for the management of gliomas]. Bull Cancer (Paris), pp.817-839, 2007.

A. Hottinger and R. Stupp, Therapeutic strategies for the management of gliomas], Rev Neurol, vol.164, pp.6-7523, 2008.

L. Bauchet, S. Zouaoui, A. Darlix, N. Menjot-de-champfleur, E. Ferreira et al., Assessment and treatment relevance in elderly glioblastoma patients. Neuro-Oncol, 2014.

Q. Ostrom, L. Bauchet, F. Davis, I. Deltour, J. Fisher et al., The epidemiology of glioma in adults: a " state of the science " review. Neuro-Oncol, 2014.

A. Romero-rojas, J. Diaz-perez, L. Ariza-serrano, D. Amaro, and A. Lozano-castillo, Primary Gliosarcoma of the Brain: Radiologic and Histopathologic Features, The Neuroradiology Journal, vol.83, issue.1, pp.639-687, 2013.
DOI : 10.1007/s11060-006-9295-x

D. Louis, H. Ohgaki, O. Wiestler, W. Cavenee, P. Burger et al., The 2007 WHO Classification of Tumours of the Central Nervous System, Acta Neuropathologica, vol.64, issue.2, pp.97-109, 2007.
DOI : 10.1093/jnen/60.9.863

C. Daumas-duport, F. Beuvon, P. Varlet, and C. Fallet-bianco, Gliomas: WHO and Sainte-Anne Hospital classifications], Ann Pathol, vol.20, issue.5, pp.413-441, 2000.

C. Daumas-duport, P. Varlet, M. Tucker, F. Beuvon, P. Cervera et al., Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases, J Neurooncol, 1997.

C. Daumas-duport, M. Tucker, H. Kolles, P. Cervera, F. Beuvon et al., Part II: A new grading system based on morphological and imaging criteria, Journal of Neuro-Oncology, vol.34, issue.1, pp.61-78, 1997.
DOI : 10.1023/A:1005759220434

M. Gerosa, D. Talarico, C. Fognani, E. Raimondi, M. Colombatti et al., Overexpression of N-ras Oncogene and Epidermal Growth Factor Receptor Gene in Human Glioblastomas, JNCI Journal of the National Cancer Institute, vol.81, issue.1, pp.63-70, 1989.
DOI : 10.1093/jnci/81.1.63

A. Mauro and A. Bulfone, Oncogenes and growth factors in gliomas, J Neurosurg Sci, vol.34, pp.3-4171, 1990.

H. Ohgaki, Genetic pathways to glioblastomas, Neuropathol Off J Jpn Soc Neuropathol, vol.25, issue.1, pp.1-7, 2005.
DOI : 10.1111/j.1440-1789.2004.00600.x

Y. Sun, W. Zhang, D. Chen, Y. Lv, J. Zheng et al., A glioma classification scheme based on coexpression modules of EGFR and PDGFRA, Proceedings of the National Academy of Sciences, vol.111, issue.9
DOI : 10.1073/pnas.0506580102

D. Sidransky, T. Mikkelsen, K. Schwechheimer, M. Rosenblum, W. Cavanee et al., Clonal expansion of p53 mutant cells is associated with brain tumour progression, Nature, vol.355, issue.6363, pp.846-853, 1992.
DOI : 10.1038/355846a0

D. Fults, D. Brockmeyer, M. Tullous, C. Pedone, and R. Cawthon, p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression, Cancer Res. Feb, vol.152, issue.3, pp.674-683, 1992.

J. Reifenberger, G. Ring, U. Gies, L. Cobbers, J. Oberstrass et al., Analysis of p53 Mutation and Epidermal Growth Factor Receptor Amplification in Recurrent Gliomas with Malignant Progression, Journal of Neuropathology and Experimental Neurology, vol.55, issue.7, 1996.
DOI : 10.1097/00005072-199607000-00007

K. Ueki, Y. Ono, J. Henson, J. Efird, A. Von-deimling et al., CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated, Cancer Res, vol.56, issue.1, pp.150-153, 1996.

C. Bouvier-labit, O. Chinot, C. Ochi, D. Gambarelli, H. Dufour et al., Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas, Neuropathology and Applied Neurobiology, vol.22, issue.5, 1998.
DOI : 10.1023/A:1005841520514

W. Shapiro and J. Shapiro, A Changing Paradigm of Glioma Biology, Hematology/Oncology Clinics of North America, vol.20, issue.6, pp.1171-91, 2006.
DOI : 10.1016/j.hoc.2006.09.010

E. Schmidt, K. Ichimura, K. Messerle, H. Goike, and V. Collins, Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours, British Journal of Cancer, vol.75, issue.1, pp.2-8, 1997.
DOI : 10.1038/bjc.1997.2

X. Zhou, Y. Li, K. Hoang-xuan, P. Laurent-puig, K. Mokhtari et al., Mutational analysis of thePTEN gene in gliomas: Molecular and pathological correlations, International Journal of Cancer, vol.15, issue.2, pp.150-154, 1999.
DOI : 10.1038/sj.onc.1201337

M. Nakamura, T. Watanabe, U. Klangby, C. Asker, K. Wiman et al., p14ARF Deletion and Methylation in Genetic Pathways to Glioblastomas, Brain Pathology, vol.18, issue.2, pp.159-68, 2001.
DOI : 10.1038/bjc.1997.2

S. Daniele, B. Costa, E. Zappelli, D. Pozzo, E. Sestito et al., Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells, Scientific Reports, vol.19, issue.1, p.9956, 2015.
DOI : 10.1016/S0304-3959(02)00041-6

G. Canute, S. Longo, J. Longo, J. Winfield, B. Nevaldine et al., Hydroxyurea accelerates the loss of epidermal growth factor receptor genes amplified as double-minute chromosomes in human glioblastoma multiforme, Neurosurgery, vol.39, issue.5, pp.976-83, 1996.

P. Wesseling, IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group, Clin Cancer Res Off J Am Assoc Cancer Res, vol.16, issue.5, pp.1597-604, 2010.

I. Chakrabarti, M. Cockburn, W. Cozen, Y. Wang, and S. Preston-martin, A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999. Cancer, pp.2798-806, 2005.

B. Mckinley, A. Michalek, R. Fenstermaker, and R. Plunkett, The impact of age and gender on the incidence of glial tumors in New York state from 1976???1995, Journal of Neurosurgery, vol.93, issue.6, pp.932-941, 2000.
DOI : 10.3171/jns.2000.93.6.0932

F. Barker, Racial/ethnic differences in survival among elderly patients with a primary glioblastoma, J Neurooncol. Kitahara CM, vol.85, issue.2, pp.171-80, 2007.

S. Sadetzki, R. Bruchim, B. Oberman, G. Armstrong, C. Lau et al., Description of selected characteristics of familial glioma patients ??? Results from the Gliogene Consortium, European Journal of Cancer, vol.49, issue.6, pp.1335-1380, 1990.
DOI : 10.1016/j.ejca.2012.11.009

P. Scarbrough, I. Akushevich, and M. Wrensch, Exploring the association between melanoma and glioma risks, Annals of Epidemiology, vol.24, issue.6, p.2014
DOI : 10.1016/j.annepidem.2014.02.010

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4111084/pdf

J. Schwartzbaum, A. Ahlbom, B. Malmer, S. Lönn, A. Brookes et al., Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res, Jul, vol.1565, issue.14, pp.6459-65, 2005.
DOI : 10.1158/0008-5472.can-04-3728

URL : http://cancerres.aacrjournals.org/content/canres/65/14/6459.full.pdf

J. Blakely, Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res, Mar, vol.166, issue.5, pp.2878-2878, 2006.

M. Scheurer, E. Amirian, Y. Cao, M. Gilbert, K. Aldape et al., Polymorphisms in the Interleukin-4 Receptor Gene are Associated with Better Survival in Patients with Glioblastoma, Clinical Cancer Research, vol.14, issue.20, pp.6640-6646, 2008.
DOI : 10.1158/1078-0432.CCR-07-4681

J. Wiemels, D. Wilson, C. Patil, J. Patoka, L. Mccoy et al., IgE, allergy, and risk of glioma: Update from the San Francisco Bay Area Adult Glioma Study in the Temozolomide era, International Journal of Cancer, vol.152, issue.3, pp.680-687, 2009.
DOI : 10.1002/ijc.24369

R. Kast, Glioblastoma Invasion, Cathepsin B, and the Potential for Both to be Inhibited by Auranofin, an Old Anti-Rheumatoid Arthritis Drug, Central European Neurosurgery, vol.71, issue.03, pp.139-181, 2010.
DOI : 10.1055/s-0029-1242756

H. Loiseau, A. Huchet, M. Rué, A. Cowppli-bony, I. Baldi et al., Epidemiology of primary brain tumor] Rev Neurol (Paris) Prevalence of glioblastoma multiforme subjects with prior herbicide exposure, J Neurosci Nurs J Am Assoc Neurosci Nurses, vol.1658924, issue.465, pp.650-70260, 1992.

S. Austin and A. Schnatter, A cohort mortality study of petrochemical workers, J Occup Med Off Publ Ind Med Assoc, vol.25, issue.4, pp.304-316, 1983.

B. Kunkle, C. Yoo, and D. Roy, Discovering gene???environment interactions in Glioblastoma through a comprehensive data integration bioinformatics method, NeuroToxicology, vol.35, pp.1-14
DOI : 10.1016/j.neuro.2012.11.001

Q. Ostrom, H. Gittleman, P. Liao, C. Rouse, Y. Chen et al., CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in, Neuro-Oncol, vol.16, issue.4, pp.1-63, 2007.

R. Stupp, W. Mason, M. Van-den-bent, M. Weller, B. Fisher et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
DOI : 10.1056/nejmoa043330

R. Stupp, M. Hegi, W. Mason, M. Van-den-bent, M. Taphoorn et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, The Lancet Oncology, vol.10, issue.5, pp.459-66, 2003.
DOI : 10.1016/S1470-2045(09)70025-7

M. Weller, J. Felsberg, C. Hartmann, H. Berger, J. Steinbach et al., Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network, Journal of Clinical Oncology, vol.27, issue.34, pp.5743-50, 2009.
DOI : 10.1200/JCO.2009.23.0805

M. Hammoud, R. Sawaya, W. Shi, P. Thall, and N. Leeds, Prognostic significance of preoperative MRI scans in glioblastoma multiforme, Journal of Neuro-Oncology, vol.126, issue.3, 1996.
DOI : 10.1007/BF00146086

C. Wang, J. Rockhill, M. Mrugala, D. Peacock, A. Lai et al., Prognostic Significance of Growth Kinetics in Newly Diagnosed Glioblastomas Revealed by Combining Serial Imaging with a Novel Biomathematical Model, Cancer Research, vol.69, issue.23, pp.9133-9173, 2009.
DOI : 10.1158/0008-5472.CAN-08-3863

R. Ramakrishna, J. Barber, G. Kennedy, A. Rizvi, R. Goodkin et al., Imaging features of invasion and preoperative and postoperative tumor burden in previously untreated glioblastoma: Correlation with survival, Surg Neurol Int, vol.1, 2010.

L. Macyszyn, H. Akbari, J. Pisapia, X. Da, M. Attiah et al., Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques. Neuro-Oncol, Kelly PJ, vol.58, 2015.
DOI : 10.1093/neuonc/nov127

URL : https://academic.oup.com/neuro-oncology/article-pdf/18/3/417/7640370/nov127.pdf

P. Kelly, Computed tomography and histologic limits in glial neoplasms: Tumor types and selection for volumetric resection, Surgical Neurology, vol.39, issue.6, pp.458-65, 1993.
DOI : 10.1016/0090-3019(93)90031-U

J. Kalpathy-cramer, E. Gerstner, K. Emblem, O. Andronesi, and B. Rosen, Advanced Magnetic Resonance Imaging of the Physical Processes in Human Glioblastoma, Cancer Research, vol.74, issue.17, pp.4622-4659, 2014.
DOI : 10.1158/0008-5472.CAN-14-0383

M. Mazurowski, A. Desjardins, and J. Malof, Imaging descriptors improve the predictive power of survival models for glioblastoma patients. Neuro-Oncol, 2013.

Z. Zhang, H. Jiang, X. Chen, J. Bai, Y. Cui et al., Identifying the survival subtypes of glioblastoma by quantitative volumetric analysis of MRI, Journal of Neuro-Oncology, vol.7, issue.1, pp.207-221, 2014.
DOI : 10.2217/pme.09.49

D. Gutman, L. Cooper, S. Hwang, C. Holder, J. Gao et al., MR Imaging Predictors of Molecular Profile and Survival: Multi-institutional Study of the TCGA Glioblastoma Data Set, Radiology, vol.267, issue.2, pp.560-569, 2013.
DOI : 10.1148/radiol.13120118

M. Mazurowski, J. Zhang, K. Peters, and H. Hobbs, Computer-extracted MR imaging features are associated with survival in glioblastoma patients, Journal of Neuro-Oncology, vol.41, issue.4, pp.483-491, 2014.
DOI : 10.1118/1.4866218

A. Baldock, S. Ahn, R. Rockne, S. Johnston, M. Neal et al., Patientspecific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomas Prognostic value of perfusion-weighted imaging in brain glioma: a prospective study, PloS One. Acta Neurochir, vol.9148, issue.285, pp.277-85, 2006.

T. Hirai, R. Murakami, H. Nakamura, M. Kitajima, H. Fukuoka et al., Prognostic Value of Perfusion MR Imaging of High-Grade Astrocytomas: Long-Term Follow-Up Study, American Journal of Neuroradiology, vol.239, issue.3, pp.1505-1515, 2008.
DOI : 10.1148/radiol.2393042031

H. Soejima, W. Zhao, and T. Mukai, gene in cancer, Biochemistry and Cell Biology, vol.137, issue.4, pp.429-466, 2005.
DOI : 10.1093/jb/mvi048

D. Kokkinakis, Methionine-stress: a pleiotropic approach in enhancing the efficacy of chemotherapy. Cancer Lett, Feb, vol.28233, issue.2, pp.195-207, 2006.

D. Beier, J. Schulz, and C. Beier, Chemoresistance of glioblastoma cancer stem cells - much more complex than expected, Molecular Cancer, vol.10, issue.1, p.128, 2011.
DOI : 10.1038/nature07567

J. Dunn, A. Baborie, F. Alam, K. Joyce, M. Moxham et al., Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy, British Journal of Cancer, vol.33, issue.1, pp.124-155, 2009.
DOI : 10.1097/nen.0b013e31815f65fb

G. Minniti, M. Salvati, A. Arcella, F. Buttarelli, D. Elia et al., Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide, Journal of Neuro-Oncology, vol.16, issue.18, pp.311-317, 2011.
DOI : 10.1007/s11060-006-9241-y

Y. Kim, S. Kim, J. Cho, J. Kim, J. Chang et al., MGMT Gene Promoter Methylation as a Potent Prognostic Factor in Glioblastoma Treated With Temozolomide-Based Chemoradiotherapy: A Single-Institution Study, International Journal of Radiation Oncology*Biology*Physics, vol.84, issue.3, pp.661-668, 2012.
DOI : 10.1016/j.ijrobp.2011.12.086

W. Xu, H. Yang, Y. Liu, Y. Yang, P. Wang et al., Oncometabolite 2- hydroxyglutarate is a competitive inhibitor of ?-ketoglutarate-dependent dioxygenases. Cancer Cell, pp.17-30, 2011.

L. Dang, J. S. Su, and S. , IDH mutations in glioma and acute myeloid leukemia, Trends in Molecular Medicine, vol.16, issue.9, pp.387-97, 2010.
DOI : 10.1016/j.molmed.2010.07.002

S. Jo, S. Lee, H. Chun, S. Lee, H. Koh et al., Cellular Defense against UVB-Induced Phototoxicity by Cytosolic NADP+-Dependent Isocitrate Dehydrogenase, Biochemical and Biophysical Research Communications, vol.292, issue.2, pp.542-551, 2002.
DOI : 10.1006/bbrc.2002.6667

B. Winkler, N. Desantis, and F. Solomon, Multiple NADPH-producing pathways control glutathione (GSH) content in retina, Experimental Eye Research, vol.43, issue.5, pp.829-876, 1986.
DOI : 10.1016/S0014-4835(86)80013-6

E. Novo, M. Parola, S. Jones, X. Zhang, J. Lin et al., Redox mechanisms in hepatic chronic wound healing and fibrogenesis An integrated genomic analysis of human glioblastoma multiforme, Fibrogenesis Tissue Repair. Science, vol.1, issue.1, 2008.

M. Labussiere, M. Sanson, A. Idbaih, and J. Delattre, IDH1 Gene Mutations: A New Paradigm in Glioma Prognosis and Therapy?, The Oncologist, vol.15, issue.2, pp.196-205, 2010.
DOI : 10.1634/theoncologist.2009-0218

J. Balss, J. Meyer, W. Mueller, A. Korshunov, C. Hartmann et al., Analysis of the IDH1 codon 132 mutation in brain tumors, Acta Neuropathologica, vol.6, issue.6, pp.597-602, 2008.
DOI : 10.1093/jnen/59.6.544

F. Bleeker, S. Lamba, S. Leenstra, D. Troost, T. Hulsebos et al., ) occur frequently in high-grade gliomas but not in other solid tumors, Human Mutation, vol.279, issue.1, pp.7-11, 2009.
DOI : 10.1016/B978-0-12-152827-0.50009-8

M. Sanson, Y. Marie, S. Paris, A. Idbaih, J. Laffaire et al., Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas, Journal of Clinical Oncology, vol.27, issue.25, pp.4150-4154, 2009.
DOI : 10.1200/JCO.2009.21.9832

T. Watanabe, S. Nobusawa, P. Kleihues, and H. Ohgaki, IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas, The American Journal of Pathology, vol.174, issue.4, pp.1149-53, 2009.
DOI : 10.2353/ajpath.2009.080958

H. Yan, D. Parsons, J. G. Mclendon, R. Rasheed, B. Yuan et al., IDH1 and IDH2 mutations in gliomas, N Engl J Med Feb, vol.19360, issue.8, pp.765-73, 2009.

M. Kang, M. Kim, J. Oh, Y. Kim, S. Song et al., Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers, International Journal of Cancer, vol.279, issue.2, pp.353-358, 2009.
DOI : 10.1042/bj1180253

P. Ward, J. Patel, D. Wise, O. Abdel-wahab, B. Bennett et al., The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell, pp.225-259, 2010.

L. Dang, D. White, S. Gross, B. Bennett, M. Bittinger et al., Cancer-associated IDH1 mutations produce 2-hydroxyglutarate, Nature, vol.50, issue.7274, pp.739-783, 2009.
DOI : 10.1038/nature08617

F. Ohka, M. Ito, M. Ranjit, T. Senga, A. Motomura et al., Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation, Tumor Biology, vol.42, issue.3, 2014.
DOI : 10.1093/ilar.42.3.189

S. Zhao, Y. Lin, W. Xu, W. Jiang, Z. Zha et al., Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1??, Science, vol.12, issue.19-20, pp.261-266, 2009.
DOI : 10.1016/j.drudis.2007.08.006

C. Frezza, D. Tennant, and E. Gottlieb, IDH1 mutations in gliomas: when an enzyme loses its grip. Cancer Cell, pp.7-9, 2010.

C. Lu, P. Ward, G. Kapoor, D. Rohle, S. Turcan et al., IDH mutation impairs histone demethylation and results in a block to cell differentiation, Nature, vol.249, issue.7390, pp.474-482, 2012.
DOI : 10.1006/excr.1999.4434

S. Turcan, D. Rohle, A. Goenka, L. Walsh, F. Fang et al., IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype, Nature, vol.25, issue.7390, pp.479-83, 2012.
DOI : 10.1634/stemcells.2007-0040

D. Choi, Glutamate neurotoxicity and diseases of the nervous system, Neuron, vol.1, issue.8, pp.623-657, 1988.
DOI : 10.1016/0896-6273(88)90162-6

B. Ahlemeyer, S. Kölker, Y. Zhu, G. Hoffmann, and J. Krieglstein, Increase in glutamate-induced neurotoxicity by activated astrocytes involves stimulation of protein kinase C, Journal of Neurochemistry, vol.16, issue.3, pp.504-519, 2002.
DOI : 10.1007/978-1-4757-9551-6_14

S. Adeberg, T. Bostel, L. König, T. Welzel, J. Debus et al., A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: a predictive factor for survival? Radiat Oncol Lond Engl, p.95, 2014.

J. Scott, N. Rewcastle, P. Brasher, D. Fulton, J. Mackinnon et al., Which glioblastoma multiforme patient will become a long-term survivor? A population-based study, Annals of Neurology, vol.12, issue.2, pp.183-191, 1999.
DOI : 10.1038/bjc.1992.273

E. Burton, K. Lamborn, P. Forsyth, J. Scott, O. Campo et al., Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors, Clin Cancer Res Off J Am Assoc Cancer Res, vol.8, issue.1, pp.180-187, 2002.

D. Krex, B. Klink, C. Hartmann, A. Von-deimling, T. Pietsch et al., Long-term survival with glioblastoma multiforme, Brain, vol.130, issue.10, pp.2596-606, 2007.
DOI : 10.1093/brain/awm204

URL : https://academic.oup.com/brain/article-pdf/130/10/2596/1070518/awm204.pdf

S. Fukushima, Y. Narita, Y. Miyakita, M. Ohno, T. Takizawa et al., A case of more than 20 years survival with glioblastoma, and development of cavernous angioma as a delayed complication of radiotherapy, Neuropathology, vol.80, issue.5, pp.576-81, 2013.
DOI : 10.3171/jns.1994.80.3.0422

N. Kloosterhof, L. Bralten, H. Dubbink, P. French, and M. Van-den-bent, Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?, The Lancet Oncology, vol.12, issue.1, pp.83-91, 2011.
DOI : 10.1016/S1470-2045(10)70053-X

C. Hartmann, B. Hentschel, M. Simon, M. Westphal, G. Schackert et al., Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations, Clinical Cancer Research, vol.19, issue.18, pp.5146-57, 2013.
DOI : 10.1158/1078-0432.CCR-13-0017

URL : http://clincancerres.aacrjournals.org/content/clincanres/19/18/5146.full.pdf

M. Weller, . Bettina, M. Hentschel, M. Simon, G. Westphal et al., Long-term survival in primary glioblastoma revisited: The contribution of isocitrate dehydrogenase mutations, Neuropathology J Clin Oncol, vol.31, issue.2027, p.2013

W. Wick, C. Meisner, B. Hentschel, M. Platten, A. Schilling et al., Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation, Neurology, vol.81, issue.17, pp.1515-1537, 2013.
DOI : 10.1212/WNL.0b013e3182a95680

N. Gerber, A. Goenka, S. Turcan, M. Reyngold, V. Makarov et al., Transcriptional diversity of long-term glioblastoma survivors. Neuro-Oncol, pp.1186-95, 2014.
DOI : 10.1093/neuonc/nou043

URL : https://academic.oup.com/neuro-oncology/article-pdf/16/9/1186/7639959/nou043.pdf

G. Keles, B. Anderson, and M. Berger, The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere, Surgical Neurology, vol.52, issue.4, pp.371-380, 1999.
DOI : 10.1016/S0090-3019(99)00103-2

K. Chaichana, A. Halthore, S. Parker, A. Olivi, J. Weingart et al., Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection, Journal of Neurosurgery, vol.114, issue.3, pp.604-616, 2011.
DOI : 10.3171/2010.4.JNS091340

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725949/pdf

N. Dea, M. Fournier-gosselin, D. Mathieu, P. Goffaux, and D. Fortin, Conclusion:, The Canadian Journal of Neurological Sciences, vol.26, issue.05, pp.632-639, 2012.
DOI : 10.3171/jns.2001.95.2.0190

K. Chaichana, P. Zadnik, J. Weingart, A. Olivi, G. Gallia et al., Multiple resections for patients with glioblastoma: prolonging survival, Journal of Neurosurgery, vol.118, issue.4, pp.812-832
DOI : 10.3171/2012.9.JNS1277

URL : http://thejns.org/doi/pdf/10.3171/2012.9.JNS1277

T. Gorlia, M. Van-den-bent, M. Hegi, R. Mirimanoff, M. Weller et al., Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3, The Lancet Oncology, vol.9, issue.1, pp.29-38, 2008.
DOI : 10.1016/S1470-2045(07)70384-4

M. Walker, S. Green, D. Byar, E. Alexander, U. Batzdorf et al., Randomized Comparisons of Radiotherapy and Nitrosoureas for the Treatment of Malignant Glioma after Surgery, New England Journal of Medicine, vol.303, issue.23, pp.1323-1332, 1980.
DOI : 10.1056/NEJM198012043032303

F. Keime-guibert, O. Chinot, L. Taillandier, S. Cartalat-carel, M. Frenay et al., Radiotherapy for Glioblastoma in the Elderly, New England Journal of Medicine, vol.356, issue.15, pp.1527-1562, 2007.
DOI : 10.1056/NEJMoa065901

M. Azoulay, F. Santos, L. Souhami, V. Panet-raymond, K. Petrecca et al., Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution, Radiation Oncology, vol.190, issue.10, p.106, 2015.
DOI : 10.1007/s00066-014-0638-9

J. Simon, T. Toubiana, P. Lang, S. Taillibert, and J. Mazeron, Radiotherapy for glioblastomas: from radiobiology to concomitant chemotherapy]. Cancer Radiothérapie J Société Fr Radiothérapie Oncol, pp.322-353, 2005.

A. Omuro, K. Beal, P. Gutin, S. Karimi, D. Correa et al., Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma, Clinical Cancer Research, vol.20, issue.19, pp.5023-5054, 2014.
DOI : 10.1158/1078-0432.CCR-14-0822

A. Brandes, A. Rigon, P. Zampieri, M. Ermani, C. Carollo et al., Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme, Cancer, vol.16, issue.2, pp.355-61, 1998.
DOI : 10.1016/0360-3016(89)90941-3

S. Grossman, O. Neill, A. Grunnet, M. Mehta, M. Pearlman et al., Phase III Study Comparing Three Cycles of Infusional Carmustine and Cisplatin Followed by Radiation Therapy With Radiation Therapy and Concurrent Carmustine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme: Eastern Cooperative Oncology Group Trial 2394, Journal of Clinical Oncology, vol.21, issue.8, pp.1485-91, 2003.
DOI : 10.1200/JCO.2003.10.035

M. Milano, P. Okunieff, R. Donatello, N. Mohile, J. Sul et al., Patterns and Timing of Recurrence After Temozolomide-Based Chemoradiation for Glioblastoma, International Journal of Radiation Oncology*Biology*Physics, vol.78, issue.4, pp.1147-55, 2010.
DOI : 10.1016/j.ijrobp.2009.09.018

T. Reithmeier, E. Graf, T. Piroth, M. Trippel, M. Pinsker et al., BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors, BMC Cancer, vol.52, issue.1, p.30, 2010.
DOI : 10.1023/A:1010624504311

URL : http://doi.org/10.1186/1471-2407-10-30

K. Kim, B. Li, J. Winer, M. Armanini, N. Gillett et al., Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo, Nature, vol.362, issue.6423, pp.841-845, 1993.
DOI : 10.1038/362841a0

A. Lai, A. Tran, P. Nghiemphu, W. Pope, O. Solis et al., Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme, Journal of Clinical Oncology, vol.29, issue.2, pp.142-150, 2011.
DOI : 10.1200/JCO.2010.30.2729

R. Addeo, F. Perri, C. Parlato, D. Vittoria, and G. , ASCO 2013: bevacizumab and glioblastoma ??? a marriage dissolution?, Current Medical Research and Opinion, vol.30, issue.9, pp.1871-1874, 2014.
DOI : 10.1185/03007995.2014.921145

URL : http://www.tandfonline.com/doi/pdf/10.1185/03007995.2014.921145?needAccess=true

M. Taphoorn, R. Henriksson, A. Bottomley, T. Cloughesy, W. Wick et al., Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma, Journal of Clinical Oncology, vol.33, issue.19, 2015.
DOI : 10.1200/JCO.2014.60.3217

N. Mladkova and A. Chakravarti, Molecular profiling in glioblastoma: Prelude to personalized treatment, Current Oncology Reports, vol.14, issue.Suppl, pp.53-61, 2009.
DOI : 10.1016/S0002-9440(10)61750-6

Y. Ruan, S. Huang, D. He, R. Gopaul, Z. Li et al., Effect of TNFRSF6B neutralization antibody on cell growth suppression and apoptosis induction in glioma cells, Neoplasma, vol.62, issue.04, 2015.
DOI : 10.4149/neo_2015_069

T. Yao, J. Zhang, M. Prados, W. Weiss, C. James et al., EGFR blockade prevents glioma escape from BRAFV600E targeted therapy, Oncotarget, 2015.
DOI : 10.18632/oncotarget.4014

URL : http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=4014&path%5B%5D=10562

M. Bredel, D. Scholtens, A. Yadav, A. Alvarez, J. Renfrow et al., NFKBIA deletion in glioblastomas, N Engl J Med Feb, vol.17364, issue.7, pp.627-664, 2011.

A. Amar, S. Dearmond, D. Spencer, P. Coopersmith, D. Ramos et al., Development of anin vitro extracellular matrix assay for studies of brain tumor cell invasion, Journal of Neuro-Oncology, vol.16, issue.1, pp.1-15, 1994.
DOI : 10.1016/B978-0-12-695680-1.50017-X

H. Zhao, C. Tang, K. Cui, B. Ang, and S. Wong, A screening platform for glioma growth and invasion using bioluminescence imaging, Journal of Neurosurgery, vol.111, issue.2, pp.238-284, 2009.
DOI : 10.3171/2008.8.JNS08644

R. Yan, P. Haopeng, F. Xiaoyuan, W. Jinsong, Z. Jiawen et al., Non-Gaussian diffusion MR imaging of glioma: comparisons of multiple diffusion parameters and correlation with histologic grade and MIB-1 (Ki-67 labeling) index, Neuroradiology, vol.46, issue.2, 2015.
DOI : 10.1097/RLI.0b013e31821eea45

S. Palfi, K. Swanson, D. Boüard, S. Chrétien, F. Oliveira et al., Correlation of in vitro infiltration with glioma histological type in organotypic brain slices, British Journal of Cancer, vol.103, issue.4, pp.745-52, 2004.
DOI : 10.1007/s004010100464

S. Rao, J. Lannutti, M. Viapiano, A. Sarkar, and J. Winter, Toward 3D Biomimetic Models to Understand the Behavior of Glioblastoma Multiforme Cells, Tissue Engineering Part B: Reviews, vol.20, issue.4, pp.314-341, 2014.
DOI : 10.1089/ten.teb.2013.0227

P. Tracqui, G. Cruywagen, D. Woodward, G. Bartoo, J. Murray et al., A mathematical model of glioma growth: the effect of chemotherapy on spatio-temporal growth, Cell Proliferation, vol.32, issue.1, pp.17-31, 1995.
DOI : 10.1001/archneur.1975.00490530053004

D. Woodward, J. Cook, P. Tracqui, G. Cruywagen, J. Murray et al., A mathematical model of glioma growth: the effect of extent of surgical resection, Cell Proliferation, vol.28, issue.6, pp.269-88, 1996.
DOI : 10.1007/978-3-662-08539-4

P. Burgess, P. Kulesa, J. Murray, and E. Alvord, The Interaction of Growth Rates and Diffusion Coefficients in a Three-dimensional Mathematical Model of Gliomas, Journal of Neuropathology and Experimental Neurology, vol.56, issue.6, pp.704-717, 1997.
DOI : 10.1097/00005072-199706000-00008

K. Swanson, E. Alvord, and J. Murray, Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy, British Journal of Cancer, vol.29, issue.1, pp.14-22, 2002.
DOI : 10.1111/j.1365-2184.1996.tb01580.x

K. Swanson, C. Bridge, J. Murray, and E. Alvord, Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion, Journal of the Neurological Sciences, vol.216, issue.1, pp.1-10, 2003.
DOI : 10.1016/j.jns.2003.06.001

A. Gooya, G. Biros, and C. Davatzikos, Deformable Registration of Glioma Images Using EM Algorithm and Diffusion Reaction Modeling, IEEE Transactions on Medical Imaging, vol.30, issue.2, pp.375-90, 2011.
DOI : 10.1109/TMI.2010.2078833

K. Swanson, R. Rostomily, and E. Alvord, A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle, British Journal of Cancer, vol.170, issue.1, pp.113-122, 2008.
DOI : 10.1002/(SICI)1096-9098(199912)72:4<199::AID-JSO4>3.0.CO;2-O

E. Mandonnet, J. Pallud, D. Fontaine, L. Taillandier, L. Bauchet et al., Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection, Neurosurgical Review, vol.26, issue.8, pp.91-97, 2010.
DOI : 10.1007/s10143-009-0229-x

URL : https://hal.archives-ouvertes.fr/hal-00492516

J. Talairach and P. Tournoux, Co-Planar stereotaxic Atlas of the human brain, 1988.

D. Iosifescu, M. Shenton, S. Warfield, R. Kikinis, J. Dengler et al., An Automated Registration Algorithm for Measuring MRI Subcortical Brain Structures, NeuroImage, vol.6, issue.1, pp.13-25, 1997.
DOI : 10.1006/nimg.1997.0274

C. Holmes, R. Hoge, L. Collins, R. Woods, A. Toga et al., Enhancement of MR Images Using Registration for Signal Averaging, Journal of Computer Assisted Tomography, vol.22, issue.2, pp.324-357, 1998.
DOI : 10.1097/00004728-199803000-00032

D. Collins, P. Neelin, T. Peters, and A. Evans, Automatic 3D Intersubject Registration of MR Volumetric Data in Standardized Talairach Space, Journal of Computer Assisted Tomography, vol.18, issue.2, pp.192-205, 1994.
DOI : 10.1097/00004728-199403000-00005

V. Fonov, A. Evans, K. Botteron, C. Almli, R. Mckinstry et al., Unbiased average age-appropriate atlases for pediatric studies, NeuroImage, vol.54, issue.1, pp.313-340, 2011.
DOI : 10.1016/j.neuroimage.2010.07.033

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962759/pdf

J. Mazziotta, A. Toga, A. Evans, P. Fox, J. Lancaster et al., A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM), Philosophical Transactions of the Royal Society B: Biological Sciences, vol.356, issue.1412, 2001.
DOI : 10.1098/rstb.2001.0915

K. Swanson, E. Alvord, and J. Murray, A quantitaive model for differential motility of gliomas in grey and white matter, pp.317-346, 2000.

O. Clatz, M. Sermesant, P. Bondiau, H. Delingette, S. Warfield et al., Realistic simulation of the 3-D growth of brain tumors in MR images coupling diffusion with biomechanical deformation, IEEE Transactions on Medical Imaging, vol.24, issue.10, pp.1334-1380, 2005.
DOI : 10.1109/TMI.2005.857217

S. Jbabdi, E. Mandonnet, H. Duffau, L. Capelle, K. Swanson et al., Simulation of anisotropic growth of low-grade gliomas using diffusion tensor imaging, Magnetic Resonance in Medicine, vol.6, issue.3, pp.616-640, 2005.
DOI : 10.1016/S0002-9440(10)64183-1

E. Stretton, E. Geremia, B. Menze, H. Delingette, and N. Ayache, Importance of patient DTI's to accurately model glioma growth using the reaction diffuse equation equation, ISBI, 2013.

E. Stretton, E. Mandonnet, E. Geremia, B. Menze, . Delingette-h et al., Predicting the Location of Glioma Recurrence after a Resection Surgery, Medical Image Computing and Computer-Assisted Intervention, 2012.
DOI : 10.1007/978-3-642-33555-6_10

URL : https://hal.archives-ouvertes.fr/hal-00813870

P. Kleihues, D. Louis, B. Scheithauer, L. Rorke, G. Reifenberger et al., The WHO Classification of Tumors of the Nervous System, Journal of Neuropathology & Experimental Neurology, vol.61, issue.3, pp.215-240, 2002.
DOI : 10.1093/jnen/61.3.215

D. Loussouarn, L. Loupp, A. Frenel, J. Leclair, F. et al., Comparison of immunohistochemistry, DNA sequencing and allelespecific PCR for the detection of IDH1 mutations in gliomas, Int J Oncol, 2012.

J. Frenel, C. Leux, D. Loussouarn, L. Loupp, A. Leclair et al., Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience, Journal of Neuro-Oncology, vol.47, issue.1, pp.85-91, 2013.
DOI : 10.1016/j.ejca.2010.11.031

V. Quillien, A. Lavenu, L. Karayan-tapon, C. Carpentier, M. Labussière et al., Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA- methyltranferase in a series of 100 glioblastoma patients. Cancer, pp.4201-4212, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00667080

V. Quillien, A. Lavenu, M. Sanson, M. Legrain, P. Dubus et al., Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients, Journal of Neuro-Oncology, vol.124, issue.3, 2014.
DOI : 10.1007/s00401-012-1016-2

URL : https://hal.archives-ouvertes.fr/hal-00935512

C. Gerin, J. Pallud, C. Deroulers, P. Varlet, C. Oppenheim et al., Quantitative characterization of the imaging limits of diffuse low-grade oligodendrogliomas. Neuro-Oncol, pp.1379-88, 2013.

J. Mineo, A. Bordron, M. Baroncini, C. Ramirez, C. Maurage et al., Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients, Acta Neurochirurgica, vol.57, issue.7, 2007.
DOI : 10.1215/S1522851798000179

E. Mandonnet, L. Capelle, and H. Duffau, Extension of paralimbic low grade gliomas: toward an anatomical classification based on white matter invasion patterns, Journal of Neuro-Oncology, vol.12, issue.2, pp.179-85, 2006.
DOI : 10.1016/S0002-9440(10)64183-1

URL : https://hal.archives-ouvertes.fr/inserm-00147499

D. Johnson, O. Neill, and B. , Glioblastoma survival in the United States before and during the temozolomide era, Journal of Neuro-Oncology, vol.25, issue.2, pp.359-64
DOI : 10.1200/JCO.2007.12.2440

P. Rønning, E. Helseth, T. Meling, and T. Johannesen, A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro- Oncol, pp.1178-84, 2012.

F. Vertosick and R. Selker, Long-term survival after the diagnosis of malignant glioma: A series of 22 patients surviving more than 4 years after diagnosis, Surgical Neurology, vol.38, issue.5, pp.359-63, 1992.
DOI : 10.1016/0090-3019(92)90022-F

D. Johnson, D. Ma, J. Buckner, and J. Hammack, Conditional probability of long-term survival in glioblastoma, Cancer, vol.30, issue.5, pp.5608-5621, 2012.
DOI : 10.1159/000115440

N. Shinojima, M. Kochi, J. Hamada, H. Nakamura, S. Yano et al., The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme, Journal of Neurosurgery, vol.101, issue.2, pp.219-245, 2004.
DOI : 10.3171/jns.2004.101.2.0219

R. Mclendon and E. Halperin, Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer, pp.1745-1753, 2003.

N. Shah, B. Lin, Z. Sibenaller, T. Ryken, H. Lee et al., Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBM, PLoS ONE, vol.121, issue.1, p.16146, 2011.
DOI : 10.1371/journal.pone.0016146.s005

M. Gilbert, M. Wang, K. Aldape, R. Stupp, M. Hegi et al., Dosedense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial, J Clin Oncol Off J Am Soc Clin Oncol, issue.32, pp.314085-91, 2013.

N. Gerber, A. Goenka, S. Turcan, M. Reyngold, V. Makarov et al., Transcriptional diversity of long-term glioblastoma survivors. Neuro-Oncol, pp.1186-95, 2014.

K. Zhang, X. Wang, B. Zhou, and L. Zhang, The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis, Familial Cancer, vol.19, issue.6, 2013.
DOI : 10.1097/CCO.0b013e3282f075f3

H. Cheng, W. Yue, C. Xie, R. Zhang, S. Hu et al., IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis, Tumor Biology, vol.29, issue.6, 2013.
DOI : 10.1007/s10014-012-0090-4

G. Reifenberger, R. Weber, V. Riehmer, K. Kaulich, E. Willscher et al., Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling, International Journal of Cancer, vol.31, issue.Suppl 5, pp.1822-1853, 2014.
DOI : 10.1200/JCO.2013.49.6968

A. Amelot, D. Cremoux, P. Quillien, V. Polivka, M. Adle-biassette et al., IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients, PLOS ONE, vol.12, issue.7, p.130596, 2015.
DOI : 10.1371/journal.pone.0130596.t004

URL : https://hal.archives-ouvertes.fr/hal-01305489

R. Molenaar, D. Verbaan, S. Lamba, C. Zanon, J. Jeuken et al., The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone, Neuro-Oncology, vol.16, issue.9, pp.1263-73, 2014.
DOI : 10.1093/neuonc/nou005

P. Kelly, Gliomas: Survival, origin and early detection, Surgical Neurology International, vol.1, issue.1, p.96, 2010.
DOI : 10.4103/2152-7806.74243

URL : https://doi.org/10.4103/2152-7806.74243

E. Konukoglu, O. Clatz, P. Bondiau, H. Delingette, and N. Ayache, Extrapolating glioma invasion margin in brain magnetic resonance images: Suggesting new irradiation margins, Medical Image Analysis, vol.14, issue.2, pp.111-136, 2010.
DOI : 10.1016/j.media.2009.11.005

URL : https://hal.archives-ouvertes.fr/inria-00616107

E. Konukoglu, O. Clatz, B. Menze, B. Stieltjes, M. Weber et al., Image Guided Personalization of Reaction-Diffusion Type Tumor Growth Models Using Modified Anisotropic Eikonal Equations, IEEE Transactions on Medical Imaging, vol.29, issue.1, 2010.
DOI : 10.1109/TMI.2009.2026413

URL : https://hal.archives-ouvertes.fr/inria-00616100

L. Bohman, K. Swanson, J. Moore, R. Rockne, C. Mandigo et al., Magnetic Resonance Imaging Characteristics of Glioblastoma Multiforme: Implications for Understanding Glioma Ontogeny, Neurosurgery, vol.67, issue.5, 2010.
DOI : 10.1227/NEU.0b013e3181f556ab

D. Lim, S. Cha, M. Mayo, M. Chen, E. Keles et al., Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro-Oncol, pp.424-433, 2007.

O. Hamid, C. Robert, A. Daud, F. Hodi, W. Hwu et al., Safety and Tumor Responses with Lambrolizumab (Anti???PD-1) in Melanoma, New England Journal of Medicine, vol.369, issue.2, pp.134-178, 2013.
DOI : 10.1056/NEJMoa1305133

A. Berghoff, B. Kiesel, G. Widhalm, O. Rajky, G. Ricken et al., Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma, Neuro-Oncology, vol.17, issue.8, pp.1064-75, 2015.
DOI : 10.1093/neuonc/nou307

URL : https://academic.oup.com/neuro-oncology/article-pdf/17/8/1064/16856199/nou307.pdf

H. Akbari, L. Macyszyn, X. Da, M. Bilello, R. Wolf et al., Imaging Surrogates of Infiltration Obtained Via Multiparametric Imaging Pattern Analysis Predict Subsequent Location of Recurrence of Glioblastoma, Neurosurgery, vol.78, issue.4, pp.572-80
DOI : 10.1227/NEU.0000000000001202